Next Article in Journal
Asymmetric Organocatalytic Mannich Reaction in the Synthesis of Hybrid Isoindolinone-Pyrazole and Isoindolinone-Aminal from Functionalized α-Amidosulfone
Next Article in Special Issue
Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity
Previous Article in Journal
Update on the Role and Regulatory Mechanism of Extracellular Matrix in the Pathogenesis of Uterine Fibroids
Previous Article in Special Issue
The Glycoprotein (GP)Ib-IX-V Complex on Platelets: GPIbα Protein Expression Is Reduced in HeartMate 3 Patients with Bleeding Complications within the First 3 Months
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 6
10.3390/ijms24065779
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antiplatelet Effect of Daphnetin Is Regulated by cPLA2-Mediated Thromboxane A2 Generation in Mice

by
Preeti Kumari Chaudhary
,
Sanggu Kim
and
Soochong Kim
*
College of Veterinary Medicine, Chungbuk National University, Cheongju 28644, Republic of Korea
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(6), 5779; https://doi.org/10.3390/ijms24065779
Submission received: 13 January 2023 / Revised: 14 March 2023 / Accepted: 14 March 2023 / Published: 17 March 2023
(This article belongs to the Special Issue Advances in Platelet Biology and Functions)
Browse Figures
Review Reports Versions Notes

Abstract

:
Coumarin derivatives have been recognized for their antithrombotic, anti-inflammatory, and antioxidant properties, and daphnetin is one of the natural coumarin derivatives isolated from Daphne Koreana Nakai. Although the pharmacological value of daphnetin is well documented in diverse biological activities, its antithrombotic effect has not been studied to date. Here, we characterized the role and underlying mechanism of daphnetin in the regulation of platelet activation using murine platelets. In order to check the effect of daphnetin on platelet function, we first measured the effect of daphnetin on platelet aggregation and secretion. Collagen-induced platelet aggregation and dense granule secretion were partially inhibited by daphnetin. Interestingly, 2-MeSADP-induced secondary waves of aggregation and secretion were completely inhibited by daphnetin. It is known that 2-MeSADP-induced secretion and the resultant secondary wave of aggregation are mediated by the positive feedback effect of thromboxane A2 (TxA2) generation, suggesting the important role of daphnetin on TxA2 generation in platelets. Consistently, daphnetin did not affect the 2-MeSADP-induced platelet aggregation in aspirinated platelets where the contribution of TxA2 generation was blocked. Additionally, platelet aggregation and secretion induced by a low concentration of thrombin, which is affected by the positive feedback effect of TxA2 generation, were partially inhibited in the presence of daphnetin. Importantly, 2-MeSADP- and thrombin-induced TxA2 generation was significantly inhibited in the presence of daphnetin, confirming the role of daphnetin on TxA2 generation. Finally, daphnetin significantly inhibited 2-MeSADP-induced cytosolic phospholipase A2 (cPLA2) and ERK phosphorylation in non-aspirinated platelets. Only cPLA2 phosphorylation, not ERK phosphorylation, was significantly inhibited by daphnetin in aspirinated platelets. In conclusion, daphnetin plays a critical role in platelet function by inhibiting TxA2 generation through the regulation of cPLA2 phosphorylation.

1. Introduction

Arterial thrombosis can cause a number of cardiovascular diseases (CVDs), including myocardial infarction, atherosclerosis, and ischemic stroke. Since platelet activation plays a substantial role in these disorders, it is clear that inhibiting platelet activation is an effective therapeutic target for arterial thrombosis. After an injury exposes the vascular sub-endothelial extracellular matrix, collagen activates platelets via the glycoprotein VI (GPVI)-mediated phospholipase Cγ2 (PLCγ2) signaling pathway by activating immuno-receptor tyrosine-based activation motif (ITAM)-containing tyrosine phosphorylation of the Fc receptor (FcR) γ-chain [1]. The activation then results in the release of various G-protein-coupled receptor (GPCR) agonists, including adenosine diphosphate (ADP), thrombin, epinephrine, and serotonin, as well as TxA2 generation, which then cross-talk via their respective GPCR-specific signaling pathways to cause platelet aggregation. ADP is an important agonist that induces platelet aggregation by co-activation of both the Gq-coupled P2Y1 and Gi-coupled P2Y12 receptors [2]. Similarly, thrombin mediates its effect via protease-activated receptors (PARs) that couple to Gq and G12/13. PARs indirectly stimulate Gi through secreted ADP-induced P2Y12 receptor activation [3]. Importantly, ADP causes the generation of TxA2 from platelets that acts as a positive feedback mediator in activating platelet secretion and the resultant secondary wave of aggregation, and it stabilizes the hemostatic plug [4,5]. Likewise, thrombin also induces TxA2 generation in platelets, which contributes to potentiation of platelet aggregation and secretion induced by a low concentration of thrombin [6,7]. Platelet agonists can also activate cPLA2 that liberates arachidonic acid (AA) from the membrane that produces TxA2 [8].
Dietary supplements have a crucial role in the prevention of many human diseases, including CVDs. A number of phytochemicals have the ability to prevent and cure a number of illnesses with little to no negative side effects. Among them, coumarins, belonging to the benzopyrone family, have been used to prevent and treat a variety of diseases [9]. Some naturally occurring coumarin derivatives include warfarin, umbelliferone, esculetin, herniarin, psoralen, and imperatorin, among which some derivatives inhibit the formation of blood clots, deep vein thrombosis, and pulmonary embolism, and they are used as oral anticoagulants. However, it should be noted that the dicoumarol group of anticoagulant medications, including warfarin, is responsible for their negative effects, namely bleeding disorders. Several other naturally occurring coumarin derivatives have been shown to have an antithrombotic effect by directly inhibiting platelet activation rather than affecting the whole coagulation system. The coumarin derivative AD6 has been shown to inhibit the release of AA by inhibiting PLA2 in human platelets stimulated by thrombin [10]. Very recently, esculetin was shown to exhibit an antiplatelet effect by obstructing the collagen-induced PLCγ2/protein kinase C (PKC) cascade and AKT activation [11]. Similarly, another coumarin derivative, columbianadin, has been shown to inhibit PLCγ2, PKC, AKT, and ERK1/2 and markedly hinder integrin αIIbβ3 activation in collagen-activated platelets [12]. Esculetin has also been shown to inhibit nuclear factor kappa B (NF-κB)-dependent αIIbβ3 activation [13].
Daphnetin is a natural coumarin derivative extracted from plants of the genus Daphne [14]. It has been demonstrated to have a number of biological characteristics, including anti-inflammatory, anti-hypoxic, antimicrobial, anti-proliferative, and anti-cancerous [15,16,17]. In China, coagulation disease is now being treated therapeutically with daphnetin, suggesting that it can be a promising therapeutic approach for thrombosis. Although the pharmacological value of daphnetin is well-documented in diverse biological activities, its potential to interfere with platelet signaling and the molecular mechanism behind it are two aspects of its antithrombotic impact that have not yet been investigated.
In the present study, we examined the effect of daphnetin on platelet function and explored the molecular mechanism using murine platelets. We have shown that daphnetin inhibits 2-MeSADP-induced secretion and the resultant secondary wave of aggregation in non-aspirinated platelets. We have further shown that daphnetin does not have any effect on 2-MeSADP-induced aggregation in aspirinated platelets, suggesting that daphnetin exerts its antiplatelet effect by regulating TxA2 generation. Finally, we have shown that 2-MeSADP-induced TxA2 generation and cPLA2 phosphorylation are inhibited in the presence of daphnetin. In conclusion, daphnetin plays a role in platelet function by inhibiting TxA2 generation through the regulation of cPLA2 phosphorylation.

2. Results

2.1. The Effect of Daphnetin on GPVI-Mediated Platelet Activation

To check whether daphnetin, like other coumarin derivatives, has any role in the regulation of GPVI-mediated platelet response, we first stimulated the platelets with various concentrations of collagen and measured the platelet aggregations and dense granule secretion. As shown in Figure 1, daphnetin significantly inhibited collagen-induced dense granule secretion in a dose-dependent manner while only a high concentration of daphnetin inhibited a low concentration of collagen-induced platelet aggregation. The data suggest that daphnetin has a minor role in GPVI-mediated platelet response, unlike other coumarin derivatives.

2.2. Daphnetin Regulates 2-MeSADP-Induced Secondary Wave of Aggregation and Secretion in Platelets

To evaluate the effect of daphnetin on GPCR-mediated platelet function, we checked the effect of daphnetin on 2-MeSADP-induced platelet aggregation and secretion. In Figure 2, the secondary waves of platelet aggregation and secretion induced by both low and high concentrations of 2-MeSADP were completely inhibited by daphnetin.
It is well established that 2-MeSADP-induced secretion and the resultant secondary wave of platelet aggregation are dependent on TxA2 generation [4,18]. Therefore, we pretreated the platelets with aspirin to block the positive feedback effect of generated TxA2 and measured the platelet aggregation and dense granule secretion in response to 2-MeSADP in the presence of daphnetin. Interestingly, daphnetin did not further block 2-MeSADP-induced platelet aggregation in aspirin-treated platelets (Figure 3), suggesting the effect of daphnetin on TxA2 generation.

2.3. Daphnetin Regulates Platelet Aggregation and Secretion Induced by Low Concentration of Thrombin

To evaluate the effect of daphnetin on other agonist-induced platelet aggregation and secretion, we stimulated the platelets with thrombin in the presence of daphnetin. As shown in Figure 4, daphnetin inhibited a low concentration of thrombin-induced platelet aggregation and dense granule secretion but did not affect aggregation or secretion when platelets were stimulated with high concentrations of thrombin.

2.4. Daphnetin Regulates 2-MeSADP- and Thrombin-Induced TxA2 Generation in Platelets

To confirm the effect of daphnetin on TxA2 generation, we stimulated the platelets with 2-MeSADP and thrombin and measured the total amount of TxA2 generation. We found that 2-MeSADP- and thrombin-induced TxA2 generation was significantly inhibited by daphnetin in a dose-dependent manner (Figure 5), confirming the important role of daphnetin on TxA2 generation.

2.5. Daphnetin Inhibits 2-MeSADP-Induced cPLA2 and ERK Phosphorylation in Platelets

To determine the molecular mechanism involved in the regulation of TxA2 generation by daphnetin, we stimulated platelets with 2-MeSADP in the presence and absence of aspirin and measured the phosphorylation of cPLA2, ERK, and AKT. As shown in Figure 6, 2-MeSADP-induced cPLA2 phosphorylation was completely inhibited in the presence of daphnetin in a dose-dependent manner in both non-aspirinated and aspirinated platelets. However, 2-MeSADP-induced ERK phosphorylation was significantly inhibited by daphnetin only in non-aspirinated platelets, while daphnetin showed no effect on 2-MeSADP-induced ERK phosphorylation in aspirinated platelets. In addition, daphnetin did not have any effect on 2-MeSADP-induced AKT phosphorylation in both non-aspirinated and aspirinated platelets. The data indicate that daphnetin regulates TxA2 generation through direct inhibition of cPLA2 phosphorylation in platelets.

3. Discussion

A platelet plays a vital role in thrombosis and hemostasis. The antiplatelet medications that are most frequently prescribed include cyclooxygenase inhibitors, ADP receptor antagonists, and GPIIb/IIIa receptor antagonists [19]. Numerous phytochemicals have the preventive and therapeutic capacity to effectively treat a variety of diseases with little or no adverse effects. Because of their potential to prevent and treat a number of diseases, coumarins, among others, have sparked a revolution in the research community and have also been used as anticoagulants recently [8]. The pharmacological value of daphnetin is well documented in diverse biological activities but its antithrombotic effect is not well established to date. Therefore, our objective was to investigate the role of daphnetin and its underlying mechanism on the regulation of platelet activation using murine platelets.
Coumarin derivatives, such as esculetin and columbianadin, have been known to exert their antiplatelet effect by targeting PLCγ2 that regulates PKC-mediated MAP kinase activation, TxA2 generation, and granule secretion downstream of GPVI-mediated platelet signaling, while they have no effect on thrombin-, U46619- (a TxA2 analog), and AA-induced platelet aggregation [11,12]. However, daphnetin only partially inhibited collagen-induced platelet aggregation and secretion. If daphnetin inhibits PLCγ2 like other coumarin derivatives [11,12], we would not expect to see the aggregation in collagen-stimulated platelets in the presence of daphnetin. These data suggest that daphnetin has a minor effect in GPVI-mediated platelet response in contrast to other coumarin derivatives and may exert its antiplatelet effect via different signaling mechanisms.
Platelet GPCRs are clinically significant GPCRs that are the targets of numerous medications used to treat bleeding problems or to prevent clotting. Recently, a study that evaluated the bioactivities of many daphnetin derivatives proposed the potential of novel daphnetin-based GPCR inhibitors or activators as new therapeutic agents for the treatment of metabolic disorders [20]. This suggests that daphnetin may have a role in regulating GPCR-mediated platelet function. ADP, TxA2, and thrombin are major agonists that promote the development and stability of thrombi via GPCR-mediated signaling pathways in platelets. Unlike GPVI signaling, GPCR-mediated signaling activates Gq-dependent PLCβ to facilitate PKC activation, TxA2 generation, and granule release and causes platelet activation. We found that dense granule secretion and the resultant secondary wave of platelet aggregation induced by both low and high concentrations of 2-MeSADP were completely inhibited by daphnetin. It has been shown that ADP-induced secretion and the resultant secondary wave of aggregation are dependent on the positive feedback effect of generated TxA2 [4]. The inhibition of TxA2 generation reduces ischemic events in clinical studies, suggesting a significant role for TxA2 in in vivo regulation of hemostasis and thrombosis [21,22]. Upon blockage of the contribution of TxA2 generation by aspirin treatment, daphnetin did not show any additional inhibitory effect on 2-MeSADP-induced platelet aggregation compared to a non-aspirin-treated platelet. Taken together, our data indicate that daphnetin affects the 2-MeSADP-induced secondary wave of aggregation and secretion through the inhibition of TxA2 generation in platelets.
Thrombin is a more potent agonist than ADP that causes much stronger Gq and G12/13 stimulation [23]. It has been demonstrated that thrombin-induced platelet aggregation necessitates secreted ADP only at lower concentrations and is mediated primarily through a family of Gq-coupled PARs, independently of secreted ADP-mediated Gi signaling [3]. Thrombin-induced platelet aggregation is affected by the positive feedback effect of generated TxA2 at a lower concentration but does not depend on TxA2 generation and resultant secretion at a higher concentration [3,6]. Thus, unlike ADP, thrombin-induced platelet aggregation and secretion do not require TxA2 generation. Consistently, we found that daphnetin only affected the low concentration of thrombin-induced platelet aggregation and secretion, while the high concentration of thrombin-induced platelet aggregation and secretion were not affected by daphnetin. Importantly, we found that 2-MeSADP- and thrombin-induced TxA2 generation was significantly inhibited by daphnetin in a dose-dependent manner, confirming the effect of daphnetin on TxA2 generation. Similar to our findings, Galli et al. [10] also observed that AD6, the other coumarin derivative, was able to decrease the generation of TxB2 from endogenous AA in platelet-rich plasma (PRP) stimulated with collagen. Altogether, our data indicate that daphnetin affects the 2-MeSADP and thrombin-induced platelet function by inhibiting TxA2 generation in platelets.
The rate-limiting step in TxA2 biosynthesis by platelets is the activation of cPLA2 with the production of free AA as a substrate for cyclooxygenase (COX) [24,25]. We found that daphnetin completely inhibited 2-MeSADP-induced cPLA2 phosphorylation in both non-aspirinated and aspirinated platelets, demonstrating that daphnetin inhibits TxA2 generation by specifically targeting cPLA2 phosphorylation in platelets. It has been demonstrated that ADP-induced TxA2 generation is regulated by ERK, thus establishing an important role of ERK in TxA2 generation in platelets [4,5,18,26]. It has also been reported that mitogen-activated protein kinase (MAPK) phosphorylation including ERK is dependent on TxA2-stimulated activation of the TP receptor in various cell lines [27,28,29]. Additionally, it has been demonstrated that ERK phosphorylation is significantly intensified in a time-dependent manner upon stimulation of platelet with TxA2, thus indicating the significance of ERK in TxA2-mediated platelet activation [30]. Interestingly, 2-MeSADP-induced ERK phosphorylation was significantly inhibited by daphnetin in non-aspirinated platelets while this ERK phosphorylation was not affected by daphnetin in aspirinated platelets. It has been shown that ERK has the ability to phosphorylate cPLA2 on Ser505, which somewhat boosts cPLA2’s catalytic activity [31]. However, we found that daphnetin inhibited 2-MeSADP-induced cPLA2 phosphorylation in aspirinated platelets while having no effect on ERK phosphorylation, indicating that daphnetin does not directly target ERK to regulate cPLA2’s activity. These results indicate that daphnetin in the absence of TxA2 generation does not have any effect on ERK phosphorylation, suggesting that daphnetin regulates ERK phosphorylation by inhibiting TxA2 generation. It has been well established that AKT is activated downstream of phosphoinositide 3-kinase (PI3K) by ADP in a P2Y12 receptor-dependent Gi pathway in platelets [32], but the PI3K-AKT pathway does not play any role in the regulation of TxA2 generation. Daphnetin had no effect on 2-MeSADP-induced AKT phosphorylation in both non-aspirinated and aspirinated platelets. Taken together, our data demonstrate that daphnetin regulates 2-MeSADP-induced TxA2 generation by directly regulating cPLA2 phosphorylation in platelets.
In in vivo studies, inhibition of ERK has been shown to significantly increase survival rates in a pulmonary thromboembolism assay and time to arterial occlusion, highlighting a potential in vivo role for ERK in the regulation of thrombosis and hemostasis [33,34]. Likewise, TxA2 receptor knockout mice have been reported to have mild bleeding disorders [35]. As daphnetin regulates the platelet function by inhibiting TxA2 generation, we expect that daphnetin would have similar effects on platelet function in vivo as those were seen in the previous studies. TxA2 is a product of the oxidative metabolism of AA generated by the platelet, thereby acting in an autocrine manner to stimulate TxA2 prostanoid (TP) receptors [36]. Thus, the TxA2 pathway has been the constant target for antiplatelets. TP receptor is one such GPCR that remains resistant for therapeutic interventions. Aspirin has been frequently used as an irreversible COX inhibitor that reduces TxA2 generation and TP receptor stimulation. Despite the efficacy of aspirin, there is still interest in developing direct TP receptor antagonists in order to preserve the beneficial effects of other prostanoids such as gastric mucosal protection that are lost upon global inhibition of COX [36,37]. As daphnetin is a natural derivative, it would be beneficial to carry out an in vivo assay to further validate the physiological significance of daphnetin in thrombosis and hemostasis, and whether it can be used as an alternative therapeutic source of TxA2 inhibitors to treat various cardiovascular diseases.
In conclusion, we demonstrate that the antiplatelet effect of daphnetin is mediated by the inhibition of TxA2 generation through the regulation of cPLA2 phosphorylation. Further, it regulates generated TxA2-mediated ERK phosphorylation indirectly to regulate the platelet functional responses.

4. Materials and Methods

4.1. Materials

Collagen was purchased from Chrono-log Corporation (Havertown, PA, USA). The 2-MeSADP, thrombin, daphnetin, apyrase (type V), prostaglandin E1 (PGE1), sodium citrate, and acetylsalicylic acid (ASA) were bought from Sigma (St. Louis, MO, USA). Anti-phospho-cPLA2 (Ser505), anti-cPLA2, anti-phospho-ERK (Thr202/Tyr204), anti-ERK, Anti-phospho-AKT (Ser473), and anti-AKT antibodies were from Cell Signaling Technology (Beverly, MA, USA). Horseradish peroxidase-labeled secondary antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TxB2 ELISA kit was from Enzo Life Sciences (Exeter, UK). All additional chemicals were of reagent grade.

4.2. Animals

We obtained 8-week-old C57BL/6 mice from Orient Bio, Inc. (Seongnam-si, Gyeonggi-Do, Republic of Korea), and we housed them in a semi-pathogen-free facility. All animal experiments were performed with approval from Chungbuk National University Animal Ethics Committee (CBNUA-873-15-02).

4.3. Mouse Platelet Isolation

Isolation of platelets from murine blood was performed as previously described [38]. Whole blood was drawn by cardiac venipuncture from an equal number of both male and female mice; sodium citrate was added and spun at 100× g for 10 min at room temperature (RT) to produce PRP. The PRP was given 1 mM ASA for 30 min at 37 °C as part of the aspirin therapy. After being centrifuged at 400× g for 10 min, the platelets were pelleted. The concentration of platelets was adjusted to 2 × 108 cells/mL by re-suspending the pellets in Tyrode’s buffer (pH 7.4) with 0.05 units/mL of apyrase.

4.4. Platelet Aggregation and Dense Granule Secretion

A Lumi-aggregometer (Chrono-Log, Havertown, PA, USA) was used to measure agonist-induced platelet aggregation and granule secretion as described previously [38]. Briefly, washed platelets (250 µL) were stimulated with the different agonists, and changes in light transmission were measured. By using luciferin/luciferase reagent, the adenosine triphosphate (ATP) release from platelets was monitored to evaluate platelet dense granule secretion according to the manufacturer’s instructions.

4.5. Measurement of TxA2 Generation

Non-aspirinated washed murine platelets were prepared at a concentration of 2 × 108 platelets/mL. Platelets were stimulated with an agonist for 3.5 min in a Lumi-aggregometer and the reaction was stopped by snap freezing. Samples were kept at −80 °C until TXB2 levels were measured. Levels of TXB2 were measured in duplicates using a TxB2 ELISA Kit (Enzo, Exeter, UK), as per the manufacturer’s instructions.

4.6. Immuno-Blotting

Phosphorylations were quantified after activating the platelets with 2-MeSADP as described previously [39]. Platelets were activated and the reaction was stopped by the addition of 6.6 N perchloric acid. To separate platelet lysates, 10% SDS/PAGE was used before they were transferred to nitrocellulose membranes. Non-specific binding sites were blocked by incubating in Tris-buffered saline/Tween-milk protein for 30 min at RT. Anti-phospho-cPLA2 (Ser505), anti-cPLA2, anti-phospho-ERK (Thr202/Tyr204), anti-ERK, anti-phospho AKT (Ser473), or anti-AKT antibodies at dilutions of 1:2000, 1:2000, 1:2000, 1:2000, 1:5000, and 1:5000, respectively, were incubated with membranes overnight at 4 °C. Immune reactivity was detected after membranes were probed with goat anti-rabbit antibody using iBrightTM CL1500 imaging system (Invitrogen, Waltham, MA, USA).

4.7. Data Analysis

All statistical calculations were determined using Prism software (version 9.1). The data were shown as mean ± standard error (SE). Statistical significance was established using the one-way analysis of variance (ANOVA) followed by a post hoc Dunnett’s multiple comparison test. The normality test was conducted by using Shapiro–Wilk test and data were found to be normally distributed (p > 0.05).

Author Contributions

Conceptualization, P.K.C. and S.K. (Soochong Kim); methodology, P.K.C. and S.K. (Sanggu Kim); validation, S.K. (Soochong Kim); investigation, P.K.C. and S.K. (Soochong Kim); writing―original draft, P.K.C.; writing―review and editing, P.K.C., S.K. (Sanggu Kim) and S.K. (Soochong Kim); supervision, S.K. (Soochong Kim). All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Foundation of Republic of Korea (NRF-2022R1A2C1003638), the Basic Research Lab Program (2022R1A4A1025557) through the NRF of Republic of Korea funded by the Ministry of Science and ICT, the Republic of Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through Agriculture, Food and Rural Affairs Convergence Technologies Program for Educating Creative Global Leader, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA; 320005-4), the National IT Industry Promotion Agency (NIPA) of Republic of Korea grant funded by the Republic of Korea government (MSIT)(S2005-22-1031), and the Global Research and Development Centre (GRDC) Program through the NRF of Republic of Korea funded by the Ministry of Science and ICT (2017K1A4A3014959).

Institutional Review Board Statement

The animal study protocol was approved by the Chungbuk National University Animal Ethics Committee (CBNUA-873-15-02, approved on 1 July 2019).

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

TxA2Thromboxane A2
cPLA2Cytosolic Phospholipase A2
CVDCardiovascular disease
GPVIGlycoprotein VI
PLCγ2Glycoprotein VI
ITAMImmunoreceptor tyrosine-based activation motif
FcRγFc Receptor (FcR) γ-Chain
GPCRG-Protein-Coupled Receptor
PARProtease-Activated Receptor
AAArachidonic Acid
PKCProtein Kinase C
COXCyclooxygenase
ASAAcetylsalicylic Acid

References

  1. Du, X. Signaling and regulation of the platelet glycoprotein Ib–IX–V complex. Curr. Opin. Hematol. 2007, 14, 262–269. [Google Scholar] [CrossRef]
  2. Jin, J.; Kunapuli, S.P. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. Sci. USA 1998, 95, 8070–8074. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Kim, S.; Foster, C.; Lecchi, A.; Quinton, T.M.; Prosser, D.M.; Jin, J.; Cattaneo, M.; Kunapuli, S.P. Protease-activated receptors 1 and 4 do not stimulate Gi signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of Gisignaling. Blood J. Am. Soc. Hematol. 2002, 99, 3629–3636. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Jin, J.; Quinton, T.M.; Zhang, J.; Rittenhouse, S.E.; Kunapuli, S.P. Adenosine diphosphate (ADP)–induced thromboxane A2generation in human platelets requires coordinated signaling through integrin αIIbβ3 and ADP receptors. Blood J. Am. Soc. Hematol. 2002, 99, 193–198. [Google Scholar] [CrossRef] [PubMed]
  5. Garcia, A.; Shankar, H.; Murugappan, S.; Kim, S.; Kunapuli, S.P. Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets. Biochem. J. 2007, 404, 299–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Shankar, H.; Garcia, A.; Prabhakar, J.; Kim, S.; Kunapuli, S. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J. Thromb. Haemost. 2006, 4, 638–647. [Google Scholar] [CrossRef]
  7. Henriksen, R.A.; Samokhin, G.P.; Tracy, P.B. Thrombin-induced thromboxane synthesis by human platelets: Properties of an anion binding exosite I–independent receptor. Atertio. Thromb. Vasc. Biol. 1997, 17, 3519–3526. [Google Scholar] [CrossRef]
  8. Stalker, T.J.; Newman, D.K.; Ma, P.; Wannemacher, K.M.; Brass, L.F. Platelet Signaling. In Antiplatelet Agents; Springer: Berlin/Heidelberg, Germany, 2012; pp. 59–85. [Google Scholar]
  9. Sharifi-Rad, J.; Cruz-Martins, N.; López-Jornet, P.; Lopez, E.P.-F.; Harun, N.; Yeskaliyeva, B.; Beyatli, A.; Sytar, O.; Shaheen, S.; Sharopov, F. Natural coumarins: Exploring the pharmacological complexity and underlying molecular mechanisms. Oxidative Med. Cell. Longev. 2021, 2021, 6492346. [Google Scholar] [CrossRef] [PubMed]
  10. Porcellati, S.; Costantini, V.; Prosdocimi, M.; Stasi, M.; Pistolesi, R.; Nenci, G.; Goracci, G. The coumarin derivative AD6 inhibits the release of arachidonic acid by interfering with phospholipase A2 activity in human platelets stimulated with thrombin. Agents Actions 1990, 29, 364–373. [Google Scholar] [CrossRef] [PubMed]
  11. Hsia, C.-W.; Lin, K.-C.; Lee, T.-Y.; Hsia, C.-H.; Chou, D.-S.; Jayakumar, T.; Velusamy, M.; Chang, C.-C.; Sheu, J.-R. Esculetin, a coumarin derivative, prevents thrombosis: Inhibitory signaling on PLCγ2–PKC–AKT activation in human platelets. Int. J. Mol. Sci. 2019, 20, 2731. [Google Scholar] [CrossRef] [Green Version]
  12. Hou, S.-M.; Hsia, C.-W.; Tsai, C.-L.; Hsia, C.-H.; Jayakumar, T.; Velusamy, M.; Sheu, J.-R. Modulation of human platelet activation and in vivo vascular thrombosis by columbianadin: Regulation by integrin α IIb β 3 inside-out but not outside-in signals. J. Biomed. Sci. 2020, 27, 60. [Google Scholar] [CrossRef] [PubMed]
  13. Hsia, C.-W.; Shyu, K.-G.; Jayakumar, T.; Hsia, C.-H.; Velusamy, M.; Yang, C.-H.; Sheu, J.-R. Natural coumarin derivative esculetin regulates platelet activation via modulating NF-κB signaling in cyclic nucleotide-independent manner. Nat. Prod. Commun. 2019, 14, 1934578X19896663. [Google Scholar] [CrossRef] [Green Version]
  14. Lv, X.; Li, Y.; Xiao, Q.; Li, D. Daphnetin activates the Nrf2-dependent antioxidant response to prevent arsenic-induced oxidative insult in human lung epithelial cells. Chem. Biol. Interact. 2019, 302, 93–100. [Google Scholar] [CrossRef]
  15. Deng, H.; Zheng, M.; Hu, Z.; Zeng, X.; Kuang, N.; Fu, Y. Effects of daphnetin on the autophagy signaling pathway of fibroblast-like synoviocytes in rats with collagen-induced arthritis (CIA) induced by TNF-α. Cytokine 2020, 127, 154952. [Google Scholar] [CrossRef]
  16. Yu, W.-W.; Lu, Z.; Zhang, H.; Kang, Y.-H.; Mao, Y.; Wang, H.-H.; Ge, W.-H.; Shi, L.-Y. Anti-inflammatory and protective properties of daphnetin in endotoxin-induced lung injury. J. Agric. Food Chem. 2014, 62, 12315–12325. [Google Scholar] [CrossRef]
  17. Song, B.; Wang, Z.; Liu, Y.; Xu, S.; Huang, G.; Xiong, Y.; Zhang, S.; Xu, L.; Deng, X.; Guan, S. Immunosuppressive activity of daphnetin, one of coumarin derivatives, is mediated through suppression of NF-κB and NFAT signaling pathways in mouse T cells. PLoS ONE 2014, 9, e96502. [Google Scholar] [CrossRef]
  18. Garcia, A.; Kim, S.; Bhavaraju, K.; Schoenwaelder, S.M.; Kunapuli, S.P. Role of phosphoinositide 3-kinase β in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem. J. 2010, 429, 369–377. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Jourdi, G.; Lordkipanidzé, M.; Philippe, A.; Bachelot-Loza, C.; Gaussem, P. Current and novel antiplatelet therapies for the treatment of cardiovascular diseases. Int. J. Mol. Sci. 2021, 22, 13079. [Google Scholar] [CrossRef]
  20. Wang, Y.; Wang, J.; Fu, Z.; Sheng, R.; Wu, W.; Fan, J.; Guo, R. Syntheses and evaluation of daphnetin derivatives as novel G protein-coupled receptor inhibitors and activators. Bioorg. Chem. 2020, 104, 104342. [Google Scholar] [CrossRef] [PubMed]
  21. Hamberg, M.; Svensson, J.; Samuelsson, B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 1975, 72, 2994–2998. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Needleman, P.; Minkes, M.; Raz, A. Thromboxanes: Selective biosynthesis and distinct biological properties. Science 1976, 193, 163–165. [Google Scholar] [CrossRef]
  23. Merhi, Y. Essential Role of Protein Kinase C in Platelet Signaling. J. Biol. Chem. 2006, 281, 30024–30035. [Google Scholar]
  24. Kita, Y.; Ohto, T.; Uozumi, N.; Shimizu, T. Biochemical properties and pathophysiological roles of cytosolic phospholipase A2s. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids 2006, 1761, 1317–1322. [Google Scholar] [CrossRef] [PubMed]
  25. Ballou, L.; DeWitt, L.; Cheung, W. Substrate-specific forms of human platelet phospholipase A2. J. Biol. Chem. 1986, 261, 3107–3111. [Google Scholar] [CrossRef]
  26. Garcia, A.; Quinton, T.M.; Dorsam, R.T.; Kunapuli, S.P. Src family kinase–mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood 2005, 106, 3410–3414. [Google Scholar] [CrossRef]
  27. Gallet, C.; Blaie, S.; Lévy-Toledano, S.; Habib, A. Epidermal-growth-factor receptor and metalloproteinases mediate thromboxane A2-dependent extracellular-signal-regulated kinase activation. Biochem. J. 2003, 371, 733–742. [Google Scholar] [CrossRef] [PubMed]
  28. Gao, Y.; Tang, S.; Zhou, S.; Ware, J.A. The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor. J. Pharmacol. Exp. Ther. 2001, 296, 426–433. [Google Scholar]
  29. Miggin, S.M.; Kinsella, B.T. Thromboxane A2 receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. Biochim. Biophys. Acta BBA Mol. Cell Res. 2001, 1539, 147–162. [Google Scholar] [CrossRef] [Green Version]
  30. Huang, Z.; Liu, P.; Zhu, L.; Li, N.; Hu, H. P2X1-initiated p38 signalling enhances thromboxane A2-induced platelet secretion and aggregation. Thromb. Haemost. 2014, 112, 142–150. [Google Scholar]
  31. Gijón, M.A.; Spencer, D.M.; Siddiqi, A.R.; Bonventre, J.V.; Leslie, C.C. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that do and do not mobilize calcium: Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J. Biol. Chem. 2000, 275, 20146–20156. [Google Scholar] [CrossRef] [Green Version]
  32. Kim, S.; Jin, J.; Kunapuli, S.P. Akt activation in platelets depends on Gi signaling pathways. J. Biol. Chem. 2004, 279, 4186–4195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Oury, C.; Kuijpers, M.J.; Toth-Zsamboki, E.; Bonnefoy, A.; Danloy, S.; Vreys, I.; Feijge, M.A.; De Vos, R.; Vermylen, J.; Heemskerk, J.W. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood J. Am. Soc. Hematol. 2003, 101, 3969–3976. [Google Scholar] [CrossRef] [PubMed]
  34. Oury, C.; Daenens, K.; Hu, H.; Toth-Zsamboki, E.; Bryckaert, M.; Hoylaerts, M.F. ERK2 activation in arteriolar and venular murine thrombosis: Platelet receptor GPIb vs. P2X1. J. Thromb. Haemost. 2006, 4, 443–452. [Google Scholar] [CrossRef]
  35. Thomas, D.W.; Mannon, R.B.; Mannon, P.J.; Latour, A.; Oliver, J.A.; Hoffman, M.; Smithies, O.; Koller, B.H.; Coffman, T.M. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Investig. 1998, 102, 1994–2001. [Google Scholar] [CrossRef] [Green Version]
  36. Ting, H.J.; Murad, J.P.; Espinosa, E.V.; Khasawneh, F.T. Thromboxane A2 receptor: Biology and function of a peculiar receptor that remains resistant for therapeutic targeting. J. Cardiovasc. Pharmacol. Ther. 2012, 17, 248–259. [Google Scholar] [CrossRef]
  37. Bousser, M.-G.; Amarenco, P.; Chamorro, A.; Fisher, M.; Ford, I.; Fox, K.M.; Hennerici, M.G.; Mattle, H.P.; Rothwell, P.M.; de Cordoüe, A. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial. Lancet 2011, 377, 2013–2022. [Google Scholar] [CrossRef]
  38. Kim, S.; Cipolla, L.; Guidetti, G.; Okigaki, M.; Jin, J.; Torti, M.; Kunapuli, S.P. Distinct role of Pyk2 in mediating thromboxane generation downstream of both G12/13 and integrin αIIbβ3 in platelets. J. Biol. Chem. 2013, 288, 18194–18203. [Google Scholar] [CrossRef] [Green Version]
  39. Kim, S.; Jin, J.; Kunapuli, S.P. Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood 2006, 107, 947–954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Ijms 24 05779 g001 550
Figure 1. The effect of daphnetin on collagen-induced platelet aggregation and secretion. (A) Washed murine platelets were stimulated with GPVI agonist 3 µg/mL, 5 µg/mL, and 7.5 µg/mL collagen in the presence of different concentrations of daphnetin for 3.5 min. Platelet aggregation (top) and ATP secretion (bottom) were analyzed in a Lumi-aggregometer. Data are representative of three independent experiments (n = 3). Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are presented as mean ± SE *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.0001.
Figure 1. The effect of daphnetin on collagen-induced platelet aggregation and secretion. (A) Washed murine platelets were stimulated with GPVI agonist 3 µg/mL, 5 µg/mL, and 7.5 µg/mL collagen in the presence of different concentrations of daphnetin for 3.5 min. Platelet aggregation (top) and ATP secretion (bottom) were analyzed in a Lumi-aggregometer. Data are representative of three independent experiments (n = 3). Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are presented as mean ± SE *, p < 0.05; **, p < 0.01; ***, p < 0.005; ****, p < 0.0001.
Ijms 24 05779 g001
Ijms 24 05779 g002 550
Figure 2. The effect of daphnetin on 2-MeSADP-induced aggregation and secretion in non-aspirinated platelets. (A) Washed murine platelets were stimulated with 30 nM, 50 nM, and 100 nM 2-MeSADP in the presence of different concentrations of daphnetin. All data are representative of three independent experiments (n = 3). Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are shown as mean ± SE ***, p < 0.001; ****, p < 0.0001.
Figure 2. The effect of daphnetin on 2-MeSADP-induced aggregation and secretion in non-aspirinated platelets. (A) Washed murine platelets were stimulated with 30 nM, 50 nM, and 100 nM 2-MeSADP in the presence of different concentrations of daphnetin. All data are representative of three independent experiments (n = 3). Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are shown as mean ± SE ***, p < 0.001; ****, p < 0.0001.
Ijms 24 05779 g002
Ijms 24 05779 g003 550
Figure 3. No additional effect of daphnetin on 2-MeSADP-induced platelet aggregation in aspirinated platelets. (A) Non-ASA- and ASA-treated murine platelets were stimulated with 30 nM 2-MeSADP in the presence of 25 µM daphnetin. All tracings shown are representative of at least three different experiments (n = 3). Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are presented as mean ± SE ***, p < 0.001; ****, p < 0.0001.
Figure 3. No additional effect of daphnetin on 2-MeSADP-induced platelet aggregation in aspirinated platelets. (A) Non-ASA- and ASA-treated murine platelets were stimulated with 30 nM 2-MeSADP in the presence of 25 µM daphnetin. All tracings shown are representative of at least three different experiments (n = 3). Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are presented as mean ± SE ***, p < 0.001; ****, p < 0.0001.
Ijms 24 05779 g003
Ijms 24 05779 g004 550
Figure 4. The effect of daphnetin on thrombin-induced platelet aggregation and secretion. (A) Washed murine platelets were stimulated with 0.1 U/mL, 0.3 U/mL, and 0.5 U/mL thrombin in the presence of different concentrations of daphnetin. Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are representative of three independent experiments (n = 3) and are presented as mean ± SE *, p < 0.05; **, p < 0.01; ****, p < 0.0001.
Figure 4. The effect of daphnetin on thrombin-induced platelet aggregation and secretion. (A) Washed murine platelets were stimulated with 0.1 U/mL, 0.3 U/mL, and 0.5 U/mL thrombin in the presence of different concentrations of daphnetin. Quantification of the (B) extent of aggregation and (C) dense granule secretion from panel A. Data are representative of three independent experiments (n = 3) and are presented as mean ± SE *, p < 0.05; **, p < 0.01; ****, p < 0.0001.
Ijms 24 05779 g004
Ijms 24 05779 g005 550
Figure 5. The effect of daphnetin on TxA2 generation induced by 2-MeSADP and thrombin in platelets. Washed murine platelets were stimulated with (A) 100 nM 2-MeSADP and (B) 0.1 U/mL and 0.5 U/mL thrombin in the presence of different concentrations of daphnetin at 37 °C for 3.5 min under stirring condition and TxB2 generation were measured in duplicates by ELISA assay. Data are representative of three independent experiments (n = 3) and are presented as mean ± SE **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
Figure 5. The effect of daphnetin on TxA2 generation induced by 2-MeSADP and thrombin in platelets. Washed murine platelets were stimulated with (A) 100 nM 2-MeSADP and (B) 0.1 U/mL and 0.5 U/mL thrombin in the presence of different concentrations of daphnetin at 37 °C for 3.5 min under stirring condition and TxB2 generation were measured in duplicates by ELISA assay. Data are representative of three independent experiments (n = 3) and are presented as mean ± SE **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.
Ijms 24 05779 g005
Ijms 24 05779 g006 550
Figure 6. The effect of daphnetin on cPLA2 and ERK phosphorylation induced by 2-MeSADP in platelets. (A) Non-ASA- and ASA-treated washed platelets were stimulated with 100 nM 2-MeSADP in the presence of different concentrations of daphnetin at 37 °C for 2 min. The lysate volume corresponding to the same number of platelets was loaded. The membrane was probed with anti-phospho-cPLA2 (Ser505), anti-cPLA2, anti-phospho-ERK, anti-ERK, anti-phospho-AKT (Ser473), or anti-AKT antibodies. Data shown are representative of three independent experiments (n = 3). Blots in (B) non-ASA- and (C) ASA-treated platelets are quantified and presented as mean ± SE ***, p < 0.001; ****, p < 0.0001.
Figure 6. The effect of daphnetin on cPLA2 and ERK phosphorylation induced by 2-MeSADP in platelets. (A) Non-ASA- and ASA-treated washed platelets were stimulated with 100 nM 2-MeSADP in the presence of different concentrations of daphnetin at 37 °C for 2 min. The lysate volume corresponding to the same number of platelets was loaded. The membrane was probed with anti-phospho-cPLA2 (Ser505), anti-cPLA2, anti-phospho-ERK, anti-ERK, anti-phospho-AKT (Ser473), or anti-AKT antibodies. Data shown are representative of three independent experiments (n = 3). Blots in (B) non-ASA- and (C) ASA-treated platelets are quantified and presented as mean ± SE ***, p < 0.001; ****, p < 0.0001.
Ijms 24 05779 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Chaudhary, P.K.; Kim, S.; Kim, S. Antiplatelet Effect of Daphnetin Is Regulated by cPLA2-Mediated Thromboxane A2 Generation in Mice. Int. J. Mol. Sci. 2023, 24, 5779. https://doi.org/10.3390/ijms24065779

AMA Style

Chaudhary PK, Kim S, Kim S. Antiplatelet Effect of Daphnetin Is Regulated by cPLA2-Mediated Thromboxane A2 Generation in Mice. International Journal of Molecular Sciences. 2023; 24(6):5779. https://doi.org/10.3390/ijms24065779

Chicago/Turabian Style

Chaudhary, Preeti Kumari, Sanggu Kim, and Soochong Kim. 2023. "Antiplatelet Effect of Daphnetin Is Regulated by cPLA2-Mediated Thromboxane A2 Generation in Mice" International Journal of Molecular Sciences 24, no. 6: 5779. https://doi.org/10.3390/ijms24065779

APA Style

Chaudhary, P. K., Kim, S., & Kim, S. (2023). Antiplatelet Effect of Daphnetin Is Regulated by cPLA2-Mediated Thromboxane A2 Generation in Mice. International Journal of Molecular Sciences, 24(6), 5779. https://doi.org/10.3390/ijms24065779

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop